Circassia Acquires North American and Japanese Rights to ...( Circassia Establishes Com...)

Circassia Establishes Commercial-Scale Supply Chain

Circassia to Develop Dopexamine as Part of Proprietary Post-Surgery

Recovery Protocols

OXFORD, England, October 8 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, announced today that it has acquired the US, Canadian and Japanese development and commercialization rights to dopexamine from the international speciality pharmaceutical company Ipsen. Circassia has also entered into agreements with pharmaceutical manufacturers Excella and Hospira to establish a commercial-scale supply chain for the product.

Circassia is developing dopexamine in a new indication as an integral part of proprietary structured protocols designed to dramatically improve patient recovery following a range of high-risk surgeries. This novel approach, named ToleroCare(R), which Circassia has recently patented, combines the use of dopexamine with the administration of intra-venous fluids to improve tissue oxygenation levels during the recovery period after surgery. The precise use of fluids and dopexamine is based on carefully defined parameters such as heart stroke volume and oxygen delivery index.

ToleroCare therapy has already achieved clinical proof-of-concept in a phase II single-blind, randomized, controlled trial in 122 high-risk general surgery patients in the UK. The study showed that significantly fewer patients who received ToleroCare experienced complications in the 30 day period following surgery compared with those on standard treatment (44% vs. 68%; p = 0.003). In addition, ToleroCare patients recovered significantly quicker, staying in hospital for 17.5 days on average compared with 29.5 days (p = 0.001) for those who received standard therapy.

Dopexamine is a beta2 adrenoceptor and dopamine receptor agonist, which is approved in Europe in indications related to heart failure. Dop
'/>"/>